Across TCGA pan-cancer cohorts, CFAP36 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CFAP36 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CFAP36 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CFAP36 expression acts as an unfavorable survival marker.
UCEC are the cancer types where CFAP36 Mutation most reproducibly stratifies survival.